

Timo Deutschbein

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7461355/publications.pdf>

Version: 2024-02-01

78
papers

4,591
citations

109321

35
h-index

106344

65
g-index

79
all docs

79
docs citations

79
times ranked

4831
citing authors

#	ARTICLE	IF	CITATIONS
1	Comprehensive Molecular Characterization of Pheochromocytoma and Paraganglioma. <i>Cancer Cell</i> , 2017, 31, 181-193.	16.8	532
2	Comprehensive Pan-Genomic Characterization of Adrenocortical Carcinoma. <i>Cancer Cell</i> , 2016, 29, 723-736.	16.8	482
3	Major Prognostic Role of Ki67 in Localized Adrenocortical Carcinoma After Complete Resection. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, 841-849.	3.6	274
4	Treatment of aggressive pituitary tumours and carcinomas: results of a European Society of Endocrinology (ESE) survey 2016. <i>European Journal of Endocrinology</i> , 2018, 178, 265-276.	3.7	196
5	Genetics, diagnosis, management and future directions of research of phaeochromocytoma and paraganglioma: a position statement and consensus of the Working Group on Endocrine Hypertension of the European Society of Hypertension. <i>Journal of Hypertension</i> , 2020, 38, 1443-1456.	0.5	190
6	Mitotane Inhibits Sterol-O-Acyl Transferase 1 Triggering Lipid-Mediated Endoplasmic Reticulum Stress and Apoptosis in Adrenocortical Carcinoma Cells. <i>Endocrinology</i> , 2015, 156, 3895-3908.	2.8	153
7	The Role of Surgery in the Management of Recurrent Adrenocortical Carcinoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, 181-191.	3.6	132
8	Urine steroid metabolomics for the differential diagnosis of adrenal incidentalomas in the EURINE-ACT study: a prospective test validation study. <i>Lancet Diabetes and Endocrinology</i> , 2020, 8, 773-781.	11.4	129
9	Prognostic Role of Overt Hypercortisolism in Completely Operated Patients with Adrenocortical Cancer. <i>European Urology</i> , 2014, 65, 832-838.	1.9	121
10	Biochemical Diagnosis of Chromaffin Cell Tumors in Patients at High and Low Risk of Disease: Plasma versus Urinary Free or Deconjugated O-Methylated Catecholamine Metabolites. <i>Clinical Chemistry</i> , 2018, 64, 1646-1656.	3.2	121
11	Prognosis of Malignant Pheochromocytoma and Paraganglioma (MAPP-Prono Study): A European Network for the Study of Adrenal Tumors Retrospective Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 2367-2374.	3.6	103
12	Diagnosis of Primary Hypophysitis in Germany. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, 3841-3849.	3.6	98
13	CT Characteristics of Pheochromocytoma: Relevance for the Evaluation of Adrenal Incidentaloma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 312-318.	3.6	96
14	Treatment of Primary Hypophysitis in Germany. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, 3460-3469.	3.6	88
15	Gemcitabine-Based Chemotherapy in Adrenocortical Carcinoma: A Multicenter Study of Efficacy and Predictive Factors. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 4323-4332.	3.6	79
16	Targeting CXCR4 (CXC Chemokine Receptor Type 4) for Molecular Imaging of Aldosterone-Producing Adenoma. <i>Hypertension</i> , 2018, 71, 317-325.	2.7	77
17	Salivary cortisol as a diagnostic tool for Cushing's syndrome and adrenal insufficiency: improved screening by an automatic immunoassay. <i>European Journal of Endocrinology</i> , 2012, 166, 613-618.	3.7	71
18	Driver mutations in USP8 wild-type Cushing's disease. <i>Neuro-Oncology</i> , 2019, 21, 1273-1283.	1.2	65

#	ARTICLE	IF	CITATIONS
19	PheoSeq. Journal of Molecular Diagnostics, 2017, 19, 575-588.	2.8	63
20	Plasma steroid metabolome profiling for the diagnosis of adrenocortical carcinoma. European Journal of Endocrinology, 2019, 180, 117-125.	3.7	59
21	Pheochromocytoma and paraganglioma: clinical feature-based disease probability in relation to catecholamine biochemistry and reason for disease suspicion. European Journal of Endocrinology, 2019, 181, 409-420.	3.7	58
22	Persistence of myopathy in Cushing's syndrome: evaluation of the German Cushing's Registry. European Journal of Endocrinology, 2017, 176, 737-746.	3.7	57
23	Age-dependent and sex-dependent disparity in mortality in patients with adrenal incidentalomas and autonomous cortisol secretion: an international, retrospective, cohort study. Lancet Diabetes and Endocrinology, 2022, 10, 499-508.	11.4	55
24	Cardiometabolic Disease Burden and Steroid Excretion in Benign Adrenal Tumors. Annals of Internal Medicine, 2022, 175, 325-334.	3.9	53
25	Diagnosis of secondary adrenal insufficiency in patients with hypothalamic-pituitary disease: comparison between serum and salivary cortisol during the high-dose short synacthen test. European Journal of Endocrinology, 2009, 160, 9-16.	3.7	51
26	Reference intervals for LC-MS/MS measurements of plasma free, urinary free and urinary acid-hydrolyzed deconjugated normetanephrine, metanephrine and methoxytyramine. Clinica Chimica Acta, 2019, 490, 46-54.	1.1	50
27	Long-Term Outcome of Primary Bilateral Macronodular Adrenocortical Hyperplasia After Unilateral Adrenalectomy. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 2985-2993.	3.6	49
28	Measurements of plasma metanephrines by immunoassay vs liquid chromatography with tandem mass spectrometry for diagnosis of pheochromocytoma. European Journal of Endocrinology, 2015, 172, 251-260.	3.7	47
29	Role of MDH2 pathogenic variant in pheochromocytoma and paraganglioma patients. Genetics in Medicine, 2018, 20, 1652-1662.	2.4	45
30	Influence of various confounding variables and storage conditions on metanephrine and normetanephrine levels in plasma. Clinical Endocrinology, 2010, 73, 153-160.	2.4	44
31	Computed tomography criteria for discrimination of adrenal adenomas and adrenocortical carcinomas: analysis of the German ACC registry. European Journal of Endocrinology, 2015, 172, 415-422.	3.7	43
32	CYP2W1 Is Highly Expressed in Adrenal Glands and Is Positively Associated with the Response to Mitotane in Adrenocortical Carcinoma. PLoS ONE, 2014, 9, e105855.	2.5	41
33	Low SGK1 Expression in Human Adrenocortical Tumors Is Associated with ACTH-Independent Glucocorticoid Secretion and Poor Prognosis. Journal of Clinical Endocrinology and Metabolism, 2012, 97, E2251-E2260.	3.6	38
34	EJE PRIZE 2014: Current and evolving treatment options in adrenocortical carcinoma: where do we stand and where do we want to go?. European Journal of Endocrinology, 2014, 171, R1-R11.	3.7	37
35	Maternal and fetal outcomes in phaeochromocytoma and pregnancy: a multicentre retrospective cohort study and systematic review of literature. Lancet Diabetes and Endocrinology, 2021, 9, 13-21.	11.4	37
36	Somatic USP8 mutations are frequent events in corticotroph tumor progression causing Nelson's tumor. European Journal of Endocrinology, 2018, 178, 57-63.	3.7	37

#	ARTICLE	IF	CITATIONS
37	Sino-European Differences in the Genetic Landscape and Clinical Presentation of Pheochromocytoma and Paraganglioma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, 3295-3307.	3.6	34
38	Efficacy of Temozolomide Therapy in Patients With Aggressive Pituitary Adenomas and Carcinomas – A German Survey. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e660-e675.	3.6	34
39	Plasma metanephrines and prospective prediction of tumor location, size and mutation type in patients with pheochromocytoma and paraganglioma. <i>Clinical Chemistry and Laboratory Medicine</i> , 2021, 59, 353-363.	2.3	32
40	Outcome after resection of Adrenocortical Carcinoma liver metastases: a retrospective study. <i>BMC Cancer</i> , 2017, 17, 522.	2.6	29
41	Impact of USP8 Gene Mutations on Protein Deregulation in Cushing Disease. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 2535-2546.	3.6	29
42	Persisting Muscle Dysfunction in Cushing's Syndrome Despite Biochemical Remission. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e4490-e4498.	3.6	29
43	The New Genetic Landscape of Cushing's Disease: Deubiquitinases in the Spotlight. <i>Cancers</i> , 2019, 11, 1761.	3.7	27
44	The New Molecular Landscape of Cushing's Disease. <i>Trends in Endocrinology and Metabolism</i> , 2015, 26, 573-583.	7.1	26
45	Late-night and low-dose dexamethasone-suppressed cortisol in saliva and serum for the diagnosis of cortisol-secreting adrenal adenomas. <i>European Journal of Endocrinology</i> , 2009, 161, 747-753.	3.7	25
46	Expression of LIN28 and its regulatory microRNAs in adult adrenocortical cancer. <i>Clinical Endocrinology</i> , 2015, 82, 481-488.	2.4	25
47	A high rate of modestly elevated plasma normetanephrine in a population referred for suspected PPGL when measured in a seated position. <i>European Journal of Endocrinology</i> , 2019, 181, 301-309.	3.7	25
48	Surviving ectopic Cushing's syndrome: quality of life, cardiovascular and metabolic outcomes in comparison to Cushing's disease during long-term follow-up. <i>European Journal of Endocrinology</i> , 2018, 179, 109-116.	3.7	24
49	Cortisol-related metabolic alterations assessed by mass spectrometry assay in patients with Cushing's syndrome. <i>European Journal of Endocrinology</i> , 2017, 177, 227-237.	3.7	23
50	High evening salivary cortisol is an independent predictor of increased mortality risk in patients with systolic heart failure. <i>International Journal of Cardiology</i> , 2016, 203, 69-73.	1.7	22
51	Patterns of Lymph Node Recurrence in Adrenocortical Carcinoma: Possible Implications for Primary Surgical Treatment. <i>Annals of Surgical Oncology</i> , 2019, 26, 531-538.	1.5	22
52	Treatment of malignant pheochromocytoma with a combination of cyclophosphamide, vincristine and dacarbazine: own experience and overview of the contemporary literature. <i>Clinical Endocrinology</i> , 2015, 82, 84-90.	2.4	21
53	Adrenal wash-out CT: moderate diagnostic value in distinguishing benign from malignant adrenal masses. <i>European Journal of Endocrinology</i> , 2022, 186, 183-193.	3.7	20
54	Pregnancy in Women Previously Treated for an Adrenocortical Carcinoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, 4604-4611.	3.6	19

#	ARTICLE	IF	CITATIONS
55	Impact of 123I-MIBG Scintigraphy on Clinical Decision-Making in Pheochromocytoma and Paraganglioma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 3812-3820.	3.6	19
56	Metabolic impact of pheochromocytoma/paraganglioma: targeted metabolomics in patients before and after tumor removal. <i>European Journal of Endocrinology</i> , 2019, 181, 647-657.	3.7	19
57	Method-Specific Cortisol and Dexamethasone Thresholds Increase Clinical Specificity of the Dexamethasone Suppression Test for Cushing Syndrome. <i>Clinical Chemistry</i> , 2021, 67, 998-1007.	3.2	18
58	Prognostic Value of Aldosterone and Cortisol in Patients Hospitalized for Acutely Decompensated Chronic Heart Failure With and Without Mineralocorticoid Receptor Antagonism. <i>Journal of Cardiac Failure</i> , 2015, 21, 208-216.	1.7	17
59	Salvage Treatment of Adrenocortical Carcinoma with Trofosamide. <i>Hormones and Cancer</i> , 2016, 7, 211-218.	4.9	16
60	Treatment of Refractory Adrenocortical Carcinoma with Thalidomide: Analysis of 27 Patients from the European Network for the Study of Adrenal Tumours Registry. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2019, 127, 578-584.	1.2	15
61	Differences between immunotherapy-induced and primary hypophysitis—a multicenter retrospective study. <i>Pituitary</i> , 2021, , 1.	2.9	15
62	Long-term safety and efficacy of subcutaneous pasireotide in patients with Cushing's disease: interim results from a long-term real-world evidence study. <i>Pituitary</i> , 2019, 22, 542-551.	2.9	12
63	Computer Vision Technology in the Differential Diagnosis of Cushing's Syndrome. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2019, 127, 685-690.	1.2	12
64	Adrenomedullary function, obesity and permissive influences of catecholamines on body mass in patients with chromaffin cell tumours. <i>International Journal of Obesity</i> , 2019, 43, 263-275.	3.4	12
65	First German Guideline on Diagnostics and Therapy of Clinically Non-Functioning Pituitary Tumors. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2021, 129, 250-264.	1.2	12
66	Mass spectrometry imaging identifies metabolic patterns associated with malignant potential in pheochromocytoma and paraganglioma. <i>European Journal of Endocrinology</i> , 2021, 185, 179-191.	3.7	12
67	Head/neck paragangliomas: focus on tumor location, mutational status and plasma methoxytyramine. <i>Endocrine-Related Cancer</i> , 2022, 29, 213-224.	3.1	12
68	Confirmatory testing of primary aldosteronism with saline infusion test and LC-MS/MS. <i>European Journal of Endocrinology</i> , 2021, 184, 167-178.	3.7	11
69	Anthropometric factors have significant influence on the outcome of the GHRH-arginine test: establishment of normative data for an automated immunoassay specifically measuring 22 kDa human growth hormone. <i>European Journal of Endocrinology</i> , 2017, 176, 273-281.	3.7	8
70	Improved Diagnostic Accuracy of Clonidine Suppression Testing Using an Age-Related Cutoff for Plasma Normetanephrine. <i>Hypertension</i> , 2022, 79, 1257-1264.	2.7	8
71	Plasma Metabolome Profiling for the Diagnosis of Catecholamine Producing Tumors. <i>Frontiers in Endocrinology</i> , 2021, 12, 722656.	3.5	7
72	Lack of Ubiquitin Specific Protease 8 (USP8) Mutations in Canine Corticotroph Pituitary Adenomas. <i>PLoS ONE</i> , 2016, 11, e0169009.	2.5	7

#	ARTICLE	IF	CITATIONS
73	The Interdisciplinary Management of Newly Diagnosed Pituitary Tumors. Deutsches Ärzteblatt International, 2021, 118, 237-243.	0.9	6
74	Case Report: Consecutive Adrenal Cushingâ€™s Syndrome and Cushingâ€™s Disease in a Patient With Somatic CTNNB1, USP8, and NR3C1 Mutations. Frontiers in Endocrinology, 2021, 12, 731579.	3.5	5
75	Integrative genomic analysis reveals a conserved role for prolactin signalling in the regulation of adrenal function. Clinical and Translational Medicine, 2021, 11, e630.	4.0	4
76	Preanalytical Considerations and Outpatient Versus Inpatient Tests of Plasma Metanephrines to Diagnose Pheochromocytoma. Journal of Clinical Endocrinology and Metabolism, 2022, 107, e3689-e3698.	3.6	4
77	Rationale and design of the cardiovascular status in patients with endogenous cortisol excess study (CV-CORT-EX): a prospective non-interventional follow-up study. BMC Endocrine Disorders, 2021, 21, 11.	2.2	2
78	Response to Letter to the Editor: â€œCT Characteristics of Pheochromocytoma: Relevance for the Evaluation of Adrenal Incidentalomaâ€. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e3842-e3843.	3.6	0